文献速递流行病学与生物统计临床试验与 GCP

P2Y12抑制剂单药与阿司匹林在确诊动脉粥样硬化患者二级预防中的比较:系统综述与荟萃分析

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.
PubMed 文献 · Lancet · 2020-01-01

预防一例心肌梗死需治疗244例,临床获益存在争议。

要点

  • 卒中、全因死亡、血管性死亡及大出血风险两组间无显著差异。
  • 预防一例心肌梗死需治疗244例,临床获益 relevance 存疑。

核心结论

  • 与阿司匹林单药相比,P2Y12抑制剂单药用于二级预防与心肌梗死风险降低相关,卒中风险相当。
  • 鉴于预防一例心肌梗死需治疗244例且对全因和血管性死亡无影响,P2Y12抑制剂单药的获益临床意义存疑。

研究设计与样本

  • 系统综述与荟萃分析,纳入比较P2Y12抑制剂与阿司匹林单药用于脑血管、冠状动脉或外周动脉疾病二级预防的随机试验。
  • 检索PubMed、Embase、BioMedCentral、Google Scholar和Cochrane Central Register of Controlled Trials,检索日期为2019年12月18日。
  • 采用随机效应模型计算比值比(OR)及95%CI,异质性用I2指数评估。
  • 研究注册于PROSPERO(CRD42018115037)。

关键数值与推荐

  • 预防一例心肌梗死需治疗244例患者。
  • 无论使用何种P2Y12抑制剂类型,结果一致。

临床怎么用

  • 在确诊动脉粥样硬化患者的二级预防中,P2Y12抑制剂单药可作为阿司匹林单药的替代选择,但需权衡心肌梗死边缘性获益与临床意义的不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiplatelet therapy is recommended among patients with established atherosclerosis. We compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention. METHODS: In this systematic review and meta-analysis, all randomised trials comparing P2Y12 inhibitor with aspirin monotherapy for secondary prevention in patients with cerebrovascular, coronary, or peripheral artery disease were evaluated for inclusion. On Dec 18, 2019, we searched PubMed, Embase, BioMedCentral, Google Scholar, and the Cochrane Central Register of Controlled Trials. Additionally, we reviewed references from identified articles and searched abstracts from 2017 to 2019 presented at relevant scientific meetings. Data about year of publication, inclusion and exclusion criteria, sample size, baseline patients' features including the baseline condition determining study inclusion (ie, cerebrovascular, coronary, or peripheral artery disease), P2Y12 inhibitor type and dosage, aspirin dosage, endpoint definitions, effect estimates, follow-up duration, and percentage of patients lost to follow-up were collected. Odds ratios (ORs) and 95% CIs were used as metric of choice for treatment effects with random-effects models. Co-primary endpoints were myocardial infarction and stroke. Key secondary endpoints were all-cause death and vascular death. Heterogeneity was assessed with the I2 index. This study is registered with PROSPERO (CRD42018115037). FINDINGS: A total of nine randomised trials were identified and included in this study, and 42 108 patients randomly allocated to a P2Y12 inhibitor (n=21 043) or aspirin (n=21 065) were included in our analyses. Patients who received a P2Y12 inhibitor had a borderline reduction for the risk of myocardial infarction compared with those who received aspirin (OR 0·81 [95% CI 0·66-0·99]; I2=10·9%). Risks of stroke (OR 0·93 [0·82-1·06]; I2=34·5%), all-cause death (OR 0·98 [0·89-1·08]; I2=0%), and vascular death (OR 0·97 [0·86-1·09]; I2=0%) did not differ between patients who received a P2Y12 inhibitor and those who received aspirin. Similarly, the risk of major bleeding (OR 0·90 [0·74-1·10]; I2=3·9%) did not differ between patients who received a P2Y12 inhibitor and those who received aspirin. The number needed to treat to prevent one myocardial infarction with P2Y12 inhibitor monotherapy was 244 patients. Findings were consistent regardless of the type of P2Y12 inhibitor used. INTERPRETATION: Compared with aspirin monotherapy, P2Y12 inhibitor monotherapy is associated with a risk reduction for myocardial infarction and a comparable risk of stroke in the setting of secondary prevention. The benefit of P2Y12 inhibitor monotherapy is of debatable clinical relevance, in view of the high number needed to treat to prevent a myocardial infarction and the absence of any effect on all-cause and vascular mortality. FUNDING: Italian Ministry of Education.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020. PMID: 32386592. doi:10.1016/S0140-6736(20)30315-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。